Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

cent body surface area (BSA), a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients received either REMICADE 5 mg/kg or placebo administered at weeks 0, 2 and 6, followed by maintenance treatment every 8 weeks. The REMICADE group continued on maintenance treatments every 8 weeks. Patients in the placebo group were crossed over at week 24 to receive REMICADE 5 mg/kg at weeks 24, 26 and 30, then every 8 weeks through week 46.

In EXPRESS, through week 24, adverse events (AEs) occurred at a higher incidence in the REMICADE group (82 percent) compared with the placebo group (71 percent). The only clinically significant laboratory abnormalities that occurred more frequently in the REMICADE group compared with the placebo group were elevated liver enzyme tests. There were more serious AEs (6 percent), including one fatal infection, in the REMICADE group than in the placebo group (3 percent). AEs observed were generally consistent with those described in the prescribing information, including information regarding serious infections. Please see "Important Safety Information" below.

About EXPRESS II

EXPRESS II was a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of REMICADE in 835 adult patients with chronic, stable plaque psoriasis involving at least 10 percent BSA, a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients were randomized to induction doses of REMICADE 3 mg/kg or 5 mg/kg or placebo at weeks 0, 2 and 6. Patients in the active induction treatment groups were randomized again at week 14 to receive either scheduled or "as-needed" maintenance treatment at the same dose administered during the induction phase. Patients in the placebo group were crossed over at week 16 to receive REMICADE 5 mg/kg at weeks 16, 18 and 22, then every 8 weeks through week 46.

In EXPRESS II, through week 14 (th
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... presented at 12th Congress of European Hematology ... -- Alexion,Pharmaceuticals, Inc. today announced results from ... (eculizumab) for the,treatment of paroxysmal nocturnal hemoglobinuria ... organized by The European,Hematology Association (EHA) in ...
... over Placebo Larger at One Year than at ... 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the,benefits ... 2 study in mild-to- moderate Alzheimer's,disease were statistically ... Importantly, on every endpoint studied, the benefits,of Dimebon ...
Cached Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6
(Date:8/31/2015)... ... 31, 2015 , ... All birth control methods work best if used correctly ... among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages with a lower ... vasectomy done because they are afraid of complications. , One Stop Medical Center ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/31/2015)... ... , ... The Marietta dentists and staff at Verde Pointe Dental ... and staff ran a 5K race, the Iron Horse for Enduring Hearts on August ... sponsored the event to help support projects with funding to increase understanding of clinical ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean Journal comes after Grace ... 2015. The island of Providenciales itself received a TripAdvisor Traveller's Choice Award in ... Bay is offering a special promotion for newlyweds and honeymooners to celebrate this amazing ...
(Date:8/30/2015)... Wilmington, DE (PRWEB) , ... August 31, 2015 ... ... an exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & ... providers and organizations together, the AHCA/NCAL convention brings industry professionals from all over ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2
... State ... Center Implants Two ... TUSTIN, Calif. and SYDNEY, April 22 Sunshine Heart ... announced today that The Ohio State University Medical Center in Columbus, ...
... Parks to hold second annual Walk-a-thon event THIS SUMMERNEW YORK, ... Six Flags, and Cure Kids Cancer have teamed up once ... its "A Walk In The Park" program. This unique ... properties April 26 through July 26 offering local neighborhoods a ...
... DC Raised Tobacco Taxes--WASHINGTON, April 22 According to a ... to be a slow year for tobacco control policies on ... steps that are needed to curb tobacco use and save ... Legislated Actions on Tobacco Issues or SLATI , ...
... NIJMEGEN, The Netherlands, April 22 InteRNA,Technologies ... have entered,into a research agreement to develop ... Under the research collaboration ... InteRNA,s unique lentiviral-based miRNA,overexpression library will be ...
... one serving a week, , , WEDNESDAY, April 22 (HealthDay News) ... acids appear to have a reduced risk of heart failure, ... U.S. and Swedish researchers followed nearly 40,000 Swedish men, ages ... their health outcomes. During that time, 597 men with no ...
... Advocacy Groups Join Together to Ask President Obama for a Greater ... ... TN (PRWEB) April 22, 2009 -- In recent days, both ... a greater voice in the healthcare reform debate. Understanding that ...
Cached Medicine News:Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 2Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 3Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 4Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 2Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 4Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 2Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 3Health News:InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer 2Health News:Fatty Fish May Cut Heart Failure Risk in Men 2Health News:Millennials Push For Seat at the Table on Healthcare Reform 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: